Subsequent Events (Details) - Subsequent Event [Member]	Apr. 25, 2024 shares
Subsequent Events (Details) [Line Items]
Share exchange agreement description	Under the terms of the Share Exchange Agreement, the Shareholders of YSA (the “Shareholders”) have agreed to sell 100% of the issued and outstanding shares of YSA to the Company in exchange for the issuance of the Company’s Series A Preferred Stock, and Series X Preferred Stock, as follows
Series A Preferred Stock [Member]
Subsequent Events (Details) [Line Items]
Preferred shares will be issued to shareholder	4,500,000
Voting Rights Description	Each share of Series A Preferred Stock will carry 20:1 voting rights and will vote with the holders of Common Stock as one class, and each share will be convertible into 20 shares of Common Stock. The Series A Preferred Stock does not pay dividends, does not have a liquidation preference and is not redeemable by the Company.
Series X Preferred Stock [Member]
Subsequent Events (Details) [Line Items]
Preferred shares will be issued to shareholder	1,000,000
Voting Rights Description	Each share of Series X Preferred Stock will carry 100:1 voting rights and will vote with the holders of Common Stock as one class. The Series X Preferred Stock will provide Mr. Colvin with majority voting control of the Company, and will not be convertible into Common Stock. The Series X Preferred Stock does not pay dividends, does not have a liquidation preference and is not redeemable by the Company.

Nu-Med Plus, Inc. 10-Q